Education
About Us
Working with TipRanks
Follow Us
Conduit Pharmaceuticals (CDT)
NASDAQ:CDT
Total Valuation
Conduit Pharmaceuticals has a market cap or net worth of $5.97M. The enterprise value is ―.
Market Cap$5.97M
Enterprise Value―
Share Statistics
Conduit Pharmaceuticals has 10,273,128 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding10,273,128
Owned by Insiders68.77%
Owned by Institutions0.07%
Financial Efficiency
Conduit Pharmaceuticals’s return on equity (ROE) is -29.21 and return on invested capital (ROIC) is 44067.01%.
Return on Equity (ROE)-29.21
Return on Assets (ROA)47.32
Return on Invested Capital (ROIC)44067.01%
Return on Capital Employed (ROCE)-40.69
Revenue Per Employee153.70M
Profits Per Employee-2.97M
Employee Count6
Asset Turnover219.94
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Conduit Pharmaceuticals is 1.41. Conduit Pharmaceuticals’s PEG ratio is >-0.01.
PE Ratio1.41
PS Ratio―
PB Ratio-41.10
Price to Fair Value-41.10
Price to FCF-28.68
Price to Operating Cash Flow-28.83
PEG Ratio>-0.01
Income Statement
In the last 12 months, Conduit Pharmaceuticals had revenue of 922.22M and earned 198.43M in profits. Earnings per share was 4.88.
Revenue922.22M
Gross Profit922.22M
Operating Income266.46M
Pretax Income227.94M
Net Income198.43M
EBITDA266.46M
Earnings Per Share (EPS)4.88
Cash Flow
In the last 12 months, operating cash flow was -9.68M and capital expenditures -104.63M, giving a free cash flow of -33.98M billion.
Operating Cash Flow-9.68M
Free Cash Flow-33.98M
Free Cash Flow per Share-3.31
Dividends & Yields
Conduit Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.26
52-Week Price Change-99.82%
50-Day Moving Average1.02
200-Day Moving Average9.83
Relative Strength Index (RSI)37.60
Average Volume (3m)5.09M
Important Dates
Conduit Pharmaceuticals upcoming earnings date is ―, TBA Not Confirmed.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Conduit Pharmaceuticals as a current ratio of 0.25, with Debt / Equity ratio of 0.58%
Current Ratio0.25
Quick Ratio0.25
Debt to Market Cap0.03
Net Debt to EBITDA0.03
Interest Coverage Ratio-6.96
Taxes
In the past 12 months, Conduit Pharmaceuticals has paid -29.53M in taxes.
Income Tax-29.53M
Effective Tax Rate-0.13
Enterprise Valuation
Conduit Pharmaceuticals EV to EBITDA ratio is 1.07, with an EV/FCF ratio of -29.39.
EV to Sales0.31
EV to EBITDA1.07
EV to Free Cash Flow-29.39
EV to Operating Cash Flow-29.55
Balance Sheet
Conduit Pharmaceuticals has $370.30M in cash and marketable securities with $7.46M in debt, giving a net cash position of -$362.85M billion.
Cash & Marketable Securities$370.30M
Total Debt$7.46M
Net Cash-$362.85M
Net Cash Per Share-$35.32
Tangible Book Value Per Share-$35.50
Margins
Gross margin is 65.20%, with operating margin of 28.89%, and net profit margin of 21.52%.
Gross Margin65.20%
Operating Margin28.89%
Pretax Margin24.72%
Net Profit Margin21.52%
EBITDA Margin28.89%
EBIT Margin20.56%
Analyst Forecast
The average price target for Conduit Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―